Genetron up on EU nod for lung cancer test, COVID-19 test data

Genetron Holdings

13/07/2021 15:41

** U.S.-listed shares of Chinese medtech firm Genetron
Holdings Ltd  GTH.O  rise 5.3% to $20.41
    ** Co receives the European CE Mark for its 8-gene Lung
Cancer test, which is already being commercialized in China
 urn:newsml:reuters.com:*:nGNX71D4lW
    ** CE mark indicates conformity with health, safety and
environmental protection standards for products sold within the
European Economic Area
    ** Co also says data from FDA reference panel showed the
sensitivity of its COVID-19 RNA test was the best among cos in
China and fared well versus global cos
    ** Stock up 45.8% this year, including session's gains

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))